Cite

HARVARD Citation

    Wang, M. et al. (2015). Combined therapy with Xuezhikang and low-dose rosuvastatin provides an effective and safe therapeutic strategy for dyslipidemic patients. Clinical lipidology. pp. 243-250. [Online]. 
  
Back to record